Aarti Drugs Profile
Key Indicators
- Authorised Capital ₹ 120.00 Cr
- Paid Up Capital ₹ 91.27 Cr
- Company Age 40 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1,570.00 Cr
- Satisfied Charges ₹ 1,214.54 Cr
- Revenue Growth -9.16%
- Profit Growth -7.15%
- Ebitda -5.76%
- Net Worth 5.47%
- Total Assets -1.09%
About Aarti Drugs
Aarti Drugs Limited (ADL) is a leading Public Limited Indian Non-Government Company incorporated in India on 28 September 1984 and has a history of 40 years and four months. Its registered office is in Thane, Maharashtra, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524348 and on the National Stock Exchange(NSE) under AARTIDRUGS.
The Corporate was formerly known as Aarti Drugs Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 120.00 Cr and a paid-up capital of Rs 91.27 Cr.
The company currently has active open charges totaling ₹1,570.00 Cr. The company has closed loans amounting to ₹1,214.54 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Aarti Drugs Limited India are Adhish Patil as Cfo, Prakash Patil as Ceo, and Rushikesh Deole as Company Secretary. Harshit Savla, Harit Shah, Prakash Patil, and Nine other members serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
L37060MH1984PLC055433
- Company No.
055433
- Stock Symbol
BSE : 524348 NSE : AARTIDRUGS
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
28 Sep 1984
- Date of AGM
20 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Listed
- ROC Code
Roc Mumbai
Industry
What products or services does Aarti Drugs Limited offer?
Aarti Drugs Limited offers a wide range of products and services, including Speciality Chemicals, Pharma Ingredients & Raw Materials, Anti Infective API, Common Disease Medicines, Pharmaceutical Medicine, Antifungal Injection, Tablet & Syrup, Diabetes Medicine, Antidiabetic Drug, Dairy Products, Dairy Chemical Products.
Who are the key members and board of directors at Aarti Drugs?
Executive Team (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Harshit Savla  | Managing Director | 02-Jan-1987 | Current |
| Prakash Patil | Managing Director | 05-Jan-1985 | Current |
| Rashesh Gogri | Managing Director | 16-Aug-2012 | Current |
| Adhish Patil | CFO | 04-Apr-2014 | Current |
| Rushikesh Deole | Company Secretary | 23-Apr-2019 | Current |
Board Members (9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Bhaskar Thorat | Director | 09-May-2022 | Current |
| Neha Gada | Director | 09-May-2022 | Current |
| Hasmukh Dedhia | Director | 29-Mar-2024 | Current |
| Ankit Paleja | Director | 13-Oct-2021 | Current |
| Harit Shah | Whole-Time Director | 15-Sep-1995 | Current |
| Narendra Salvi | Director | 25-Aug-2020 | Current |
Financial Performance of Aarti Drugs.
Aarti Drugs Limited, for the financial year ended 2024, experienced Minor drop in revenue, with a 9.16% decrease. The company also saw a slight decrease in profitability, with a 7.15% decrease in profit. The company's net worth moved up by a moderate rise of 5.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aarti Drugs?
In 2024, Aarti Drugs had a promoter holding of 16.59% and a public holding of 83.42%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Tamboli Industries LimitedNeha Gada is a mutual person
Devgiri Forgings Private LimitedAjit Venugopalan is a mutual person
Mitsu Chem Plast LimitedHasmukh Dedhia is a mutual person
Asian Star Company LimitedNeha Gada is a mutual person
Alchemie Gases And Chemicals Pvt.Ltd.Uday Patil is a mutual person
Aarti Industries LtdRashesh Gogri is a mutual person
Charges (Loans)
₹1,570.00 Cr
₹1,214.54 Cr
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 1570.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Mar 2011 | Axis Bank Limited | ₹1,570.00 Cr | Open |
| 25 Jan 2024 | Others | ₹300.00 Cr | Satisfied |
| 20 Sep 2018 | Others | ₹64.00 Cr | Satisfied |
| 24 Jun 2016 | Others | ₹69.00 Cr | Satisfied |
| 21 Dec 2015 | The Shamrao Vithal Co Operative Bank Limited | ₹25.00 Cr | Satisfied |
How Many Employees Work at Aarti Drugs?
Aarti Drugs has a workforce of 1007 employees as of Feb 04, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aarti Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aarti Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
